全文获取类型
收费全文 | 3663篇 |
免费 | 348篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 196篇 |
妇产科学 | 50篇 |
基础医学 | 491篇 |
口腔科学 | 151篇 |
临床医学 | 361篇 |
内科学 | 765篇 |
皮肤病学 | 55篇 |
神经病学 | 202篇 |
特种医学 | 556篇 |
外国民族医学 | 1篇 |
外科学 | 410篇 |
综合类 | 80篇 |
一般理论 | 2篇 |
预防医学 | 252篇 |
眼科学 | 60篇 |
药学 | 158篇 |
中国医学 | 4篇 |
肿瘤学 | 227篇 |
出版年
2022年 | 23篇 |
2021年 | 35篇 |
2020年 | 20篇 |
2019年 | 24篇 |
2018年 | 52篇 |
2017年 | 27篇 |
2016年 | 43篇 |
2015年 | 60篇 |
2014年 | 65篇 |
2013年 | 110篇 |
2012年 | 115篇 |
2011年 | 114篇 |
2010年 | 123篇 |
2009年 | 103篇 |
2008年 | 116篇 |
2007年 | 137篇 |
2006年 | 111篇 |
2005年 | 125篇 |
2004年 | 112篇 |
2003年 | 106篇 |
2002年 | 112篇 |
2001年 | 77篇 |
2000年 | 111篇 |
1999年 | 103篇 |
1998年 | 174篇 |
1997年 | 157篇 |
1996年 | 162篇 |
1995年 | 119篇 |
1994年 | 109篇 |
1993年 | 93篇 |
1992年 | 57篇 |
1991年 | 64篇 |
1990年 | 67篇 |
1989年 | 103篇 |
1988年 | 81篇 |
1987年 | 84篇 |
1986年 | 76篇 |
1985年 | 83篇 |
1984年 | 55篇 |
1983年 | 51篇 |
1982年 | 51篇 |
1981年 | 33篇 |
1980年 | 48篇 |
1979年 | 29篇 |
1978年 | 28篇 |
1977年 | 31篇 |
1976年 | 38篇 |
1975年 | 45篇 |
1974年 | 18篇 |
1973年 | 21篇 |
排序方式: 共有4037条查询结果,搜索用时 15 毫秒
91.
92.
93.
94.
J Tang DJ Humes E Gemmil NT Welch SL Parsons JA Catton 《Annals of the Royal College of Surgeons of England》2013,95(5):323-328
Introduction
The high mortality and morbidity associated with resection for oesophagogastric malignancy has resulted in a conservative approach to the postoperative management of this patient group. In August 2009 we introduced an enhanced recovery after surgery (ERAS) pathway tailored to patients undergoing resection for oesophagogastric malignancy. We aimed to assess the impact of this change in practice on standard clinical outcomes.Methods
Two cohorts were studied of patients undergoing resection for oesophagogastric malignancy before (August 2008 – July 2009) and after (August 2009 – July 2010) the implementation of the ERAS pathway. Data were collected on demographics, interventions, length of stay, morbidity and in-hospital mortality.Results
There were 53 and 55 oesophagogastric resections undertaken respectively for malignant disease in each of the study periods. The median length of stay for both gastric and oesophageal resection decreased from 15 to 11 days (Mann– Whitney U, p<0.001) following implementation of the ERAS pathway. There was no significant increase in morbidity (gastric resection 23.1% vs 5.3% and oesophageal resection 25.9% vs 16.7%) or mortality (gastric resection no deaths and oesophageal resection 1.8% vs 3.6%) associated with the changes. There was a significant decrease in the number of oral contrast studies used following oesophageal resection, with a reduction from 21 (77.8%) in 2008–2009 to 6 (16.7%) in 2009–2010 (chi-squared test, p<0.0001).Conclusions
The introduction of an enhanced recovery programme following oesophagogastric surgery resulted in a significant decrease in length of median patient stay in hospital without a significant increase in associated morbidity and mortality. 相似文献95.
The differential diagnosis of ankle pain is extensive. Pathology may be classified as intra- or extra-articular. Additionally, ankle pain may be traumatic or non-traumatic. One of the unusual differential diagnoses for pain in the ankle is an accessory muscle. Magnetic resonance imaging is the radiological investigation of choice. However, this is invariably reported as normal unless one specifically looks for an accessory muscle. The purpose of this report is to highlight important features of these muscles and to draw attention to this uncommonly reported condition. 相似文献
96.
97.
98.
99.
Objective
This study seeks to examine how the extent of socioeconomic deprivation, racial and ethnic isolation, and health disadvantage differ among Medicare beneficiaries in Mississippi. Methods: Geographical information system (GIS) mappings are used in conjunction with cluster analysis to examine patterns of disparities in disease distribution, healthcare utilization and socioeconomic well-being among different counties in Mississippi.Results
Results reveal that counties in these two clusters are markedly different in terms of socio-economic well-being but are somewhat similar in terms of disease distributions and healthcare utilization.Conclusion
Addressing the geographic disparities in disease distribution and healthcare utilization that exist among the counties should be a public health priority. Specifically, health policies and programs should be renewed to target people living in counties that are either predominantly rural or predominantly Black or have higher percentages of population living below the poverty level. 相似文献100.
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections 总被引:1,自引:1,他引:0 下载免费PDF全文
Ceftaroline, the bioactive metabolite of ceftaroline fosamil (previously PPI-0903, TAK-599), is a broad-spectrum cephalosporin with potent in vitro activity against multidrug-resistant gram-positive aerobic pathogens, including methicillin-resistant Staphylococcus aureus. A randomized, observer-blinded study to evaluate the safety and efficacy of ceftaroline versus standard therapy in treating complicated skin and skin structure infections (cSSSI) was performed. Adults with cSSSI, including at least one systemic marker of inflammation, were randomized (2:1) to receive intravenous (i.v.) ceftaroline (600 mg every 12 h) or i.v. vancomycin (1 g every 12 h) with or without adjunctive i.v. aztreonam (1 g every 8 h) for 7 to 14 days. The primary outcome measure was the clinical cure rate at a test-of-cure (TOC) visit 8 to 14 days after treatment. Secondary outcomes included the microbiological success rate (eradication or presumed eradication) at TOC and the clinical relapse rate 21 to 28 days following treatment. Of 100 subjects enrolled, 88 were clinically evaluable; the clinical cure rate was 96.7% (59/61) for ceftaroline versus 88.9% (24/27) for standard therapy. Among the microbiologically evaluable subjects (i.e., clinically evaluable and having had at least one susceptible pathogen isolated at baseline), the microbiological success rate was 95.2% (40/42) for ceftaroline versus 85.7% (18/21) for standard therapy. Relapse occurred in one subject in each group (ceftaroline, 1.8%; standard therapy, 4.3%). Ceftaroline exhibited a very favorable safety and tolerability profile, consistent with that of marketed cephalosporins. Most adverse events from ceftaroline were mild and not related to treatment. Ceftaroline holds promise as a new therapy for treatment of cSSSI and other serious polymicrobial infections. 相似文献